Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sernova (TSE:SVA)
TSX:SVA
Sernova (SVA) Stock Price & Analysis
106 Followers
SVA Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.27 - C$0.99
Previous CloseC$0.31
Volume261.71K
Average Volume (3M)150.69K
Market Cap
C$92.60M
Enterprise ValueC$77.69M
Total Cash (Recent Filing)C$15.55M
Total Debt (Recent Filing)C$634.63K
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Sep 25, 2024EPS Estimate
-C$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding303,332,686
10 Day Avg. Volume259,809
30 Day Avg. Volume150,686
Standard Deviation0.26
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)29.76
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$4.50Price Target Upside1351.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Sernova News
PremiumCompany Announcements
Sernova Strengthens Leadership for Market Growth
PremiumCompany Announcements
Sernova’s Breakthrough in Diabetes Treatment Trial
PremiumCompany Announcements
Sernova Halts Public Offering Amid Market VolatilityPremiumCompany Announcements
Sernova Corp. Launches Marketed Public Offering
PremiumCompany Announcements
Sernova Welcomes New Board Member Jonathan Rigby
PremiumCompany Announcements
Sernova Corp. AGM Elects Board, Advances Therapies
PremiumCompany Announcements
Sernova Corp Announces Major Organizational ChangesPremiumCompany Announcements
Sernova Strengthens Board with Evotec’s ExpertBulls Say, Bears Say
Bulls Say
Clinical ProgressSernova continues to stand alone as a company in the space to report positive patient outcomes from a study that combines donor islets transplanted into an implantable delivery vehicle in patients with T1D.
Future CatalystsThe company is expected to have a number of near-term catalysts, including updates at major conferences and submission of an IND for postoperative hypothyroidism.
ValuationSVA is significantly undervalued as its Cell Pouch remains the best-in-class and most clinically proven cell therapy device for T1D and other potential indications.
Bears Say
Capital RaiseSernova withdrew its public offering financing due to challenging market conditions, implying a need to raise capital soon.
Cash BalanceThe company ended the quarter with a cash balance of $8.5M, which implies a relatively short cash runway at its current burn rate.
Operating CostsHigher operating costs were reported, primarily due to increased R&D expenses and one-time legal and severance costs.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.82%
Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
96.18% Public Companies and
Individual Investors
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.27 and its highest was C$0.99 in the past 12 months.
What is Sernova’s market cap?
Currently, no data Available
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Sep 25, 2024 which is in 60 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Jun 14, 2024. The company reported -C$0.03 earnings per share for the quarter, missing the consensus estimate of -C$0.027 by -C$0.003.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Undervalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is -C$0.03.
How many shares outstanding does Sernova have?
Sernova has 303,612,670 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.03 in its last earnings report, missing expectations of -C$0.027. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
---
Sernova Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$4.50 (1351.61% Upside)
C$4.50 (1351.61% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.87%
12-Months-Change
Fundamentals
Return on Equity
-310.42%
Trailing 12-Months
Asset Growth
-69.07%
Trailing 12-Months
Company Description
Sernova
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. It develops a commercially-viable treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted, prevascularized and scalable medical device.
---
SVA Stock 12 Month Forecast
Average Price Target
C$4.50
▲(1351.61% Upside)
Technical Analysis
Best Analysts Covering SVA
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-38.50%
reiterated a buy rating last month
Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.50% per trade.
---